# An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

> **NCT05477524** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 12547 (actual)

## Conditions studied

- Lyme Disease

## Interventions

- **BIOLOGICAL:** VLA15
- **OTHER:** Saline

## Key facts

- **NCT ID:** NCT05477524
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-04
- **Primary completion:** 2025-12-26
- **Final completion:** 2025-12-26
- **Target enrollment:** 12547 (ACTUAL)
- **Last updated:** 2025-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05477524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05477524, "An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05477524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*